• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Vera Therapeutics Inc. (Amendment)

    2/14/24 3:21:33 PM ET
    $VERA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $VERA alert in real time by email
    SC 13G/A 1 tm246283d2_sc13ga.htm SC 13G/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G

    (Rule 13d-102)

     

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

    TO § 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED

    PURSUANT TO § 240.13d-2

     

    (Amendment No. 2)*

     

    Vera Therapeutics, Inc.
    (Name of Issuer)
     
    Class A Common Stock
    (Title of Class of Securities)
     
    92337R101
    (CUSIP Number)
     
    31 December 2023
    (Date of Event Which Requires Filing of the Statement)

      

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    oRule 13d-1(b)
    xRule 13d-1(c)
    oRule 13d-1(d)

     

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

    Cusip No. 92337R101 13G Page 2 of 9 Pages

     

     

    1.

    NAME OF REPORTING PERSONS

    Ares Trading SA

         

    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

    (a) o

    (b) o

    3.

    SEC USE ONLY

     

            

    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Switzerland

         

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    5.

     

    SOLE VOTING POWER

    1,913,5011

         

    6.

     

    SHARED VOTING POWER

    0

         

    7.

     

    SOLE DISPOSITIVE POWER

    1,913,5011 

         

    8.

     

    SHARED DISPOSITIVE POWER

    0 

         

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    1,913,5011

         

    10.

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

    o

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    3.6%2 

         

    12.

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

    CO 

         

     

     

    1The record holder of the securities covered by this Schedule 13G is Ares Trading SA.

    Ares Trading SA is a dominantly controlled subsidiary of Merck Serono SA, Coinsins, Switzerland, an affiliate of Merck KGaA, Darmstadt, Germany. Merck Serono SA, Coinsins, Switzerland is a wholly owned indirect subsidiary of Merck KGaA, Darmstadt, Germany and E. Merck KG, Darmstadt Germany. Merck KGaA, Darmstadt, Germany is a publicly traded company (Frankfurt Stock Exchange, DAX 40) and the beneficiary of the two companies. Merck KGaA, Darmstadt Germany is dominantly controlled by E. Merck KG, Darmstadt Germany. Merck Serono SA, Coinsins, Switzerland, an affiliate of Merck KGaA, Darmstadt, Germany and Merck KGaA, Darmstadt, Germany and E. Merck KG, Darmstadt, Germany may be deemed to possess voting and dispositive power with respect to the securities held of record by Ares Trading SA.

    2This percentage is based on 52,497,462 shares of Class A Common Stock outstanding (assuming the underwriters do not exercise in full the option to purchase additional shares), as disclosed by the Issuer in its prospectus supplement dated January 29, 2024 and filed with the Securities and Exchange Commission (the “Commission”) on January 30, 2024 (the “Prospectus Supplement”).

     

     

     

     

    Cusip No. 92337R101 13G Page 3 of 9 Pages

     

     

    1.

    NAME OF REPORTING PERSONS

    Merck Serono SA, Coinsins, Switzerland, an affiliate of Merck KGaA, Darmstadt, Germany

         

    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

    (a) o

    (b) o

    3.

    SEC USE ONLY

     

            

    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Switzerland

         

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    5.

     

    SOLE VOTING POWER

    1,913,5013

         

    6.

     

    SHARED VOTING POWER

     0

         

    7.

     

    SOLE DISPOSITIVE POWER

    1,913,5013 

         

    8.

     

    SHARED DISPOSITIVE POWER

    0 

         

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    1,913,5013

         

    10.

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

    o

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    3.6%4

         

    12.

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

    CO 

         

     

     

    3The record holder of the securities covered by this Schedule 13G is Ares Trading SA. Ares Trading SA is a dominantly controlled subsidiary of Merck Serono SA, Coinsins, Switzerland, an affiliate of Merck KGaA, Darmstadt, Germany. Merck Serono SA, Coinsins, Switzerland is a wholly owned indirect subsidiary of Merck KGaA, Darmstadt, Germany and E. Merck KG, Darmstadt Germany. Merck KGaA, Darmstadt, Germany is a publicly traded company (Frankfurt Stock Exchange, DAX 40) and the beneficiary of the two companies. Merck KGaA, Darmstadt Germany is dominantly controlled by E. Merck KG, Darmstadt Germany. Merck Serono SA, Coinsins, Switzerland, an affiliate of Merck KGaA, Darmstadt, Germany and Merck KGaA, Darmstadt, Germany and E. Merck KG, Darmstadt, Germany may be deemed to possess voting and dispositive power with respect to the securities held of record by Ares Trading SA.
    4This percentage is based on 52,497,462 shares of Class A Common Stock outstanding (assuming the underwriters do not exercise in full the option to purchase additional shares), as disclosed by the Issuer in its Prospectus Supplement.

     

     

     

    Cusip No. 92337R101 13G Page 4 of 9 Pages

     

     

    1.

    NAME OF REPORTING PERSONS

    Merck KGaA, Darmstadt, Germany

         

    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

    (a) o

    (b) o

    3.

    SEC USE ONLY

     

            

    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Germany

         

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    5.

     

    SOLE VOTING POWER

    1,913,5015

         

    6.

     

    SHARED VOTING POWER

     0

         

    7.

     

    SOLE DISPOSITIVE POWER

    1,913,5015 

         

    8.

     

    SHARED DISPOSITIVE POWER

    0 

         

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     1,913,5015

         

    10.

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

    o

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    3.6%6

         

    12.

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

    CO 

         

     

     

    5The record holder of the securities covered by this Schedule 13G is Ares Trading SA. Ares Trading SA is a dominantly controlled subsidiary of Merck Serono SA, Coinsins, Switzerland, an affiliate of Merck KGaA, Darmstadt, Germany. Merck Serono SA, Coinsins, Switzerland is a wholly owned indirect subsidiary of Merck KGaA, Darmstadt, Germany and E. Merck KG, Darmstadt Germany. Merck KGaA, Darmstadt, Germany is a publicly traded company (Frankfurt Stock Exchange, DAX 40) and the beneficiary of the two companies. Merck KGaA, Darmstadt Germany is dominantly controlled by E. Merck KG, Darmstadt Germany. Merck Serono SA, Coinsins, Switzerland, an affiliate of Merck KGaA, Darmstadt, Germany and Merck KGaA, Darmstadt, Germany and E. Merck KG, Darmstadt, Germany may be deemed to possess voting and dispositive power with respect to the securities held of record by Ares Trading SA.
    6This percentage is based on 52,497,462 shares of Class A Common Stock outstanding (assuming the underwriters do not exercise in full the option to purchase additional shares), as disclosed by the Issuer in its Prospectus Supplement.

     

     

     

    Cusip No. 92337R101 13G Page 5 of 9 Pages

     

     

    1.

    NAME OF REPORTING PERSONS

    E. Merck KG, Darmstadt Germany

         

    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

    (a) o

    (b) o

    3.

    SEC USE ONLY

     

            

    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Germany

         

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    5.

     

    SOLE VOTING POWER

    1,913,5017

         

    6.

     

    SHARED VOTING POWER

    0

         

    7.

     

    SOLE DISPOSITIVE POWER

    1,913,5015 

         

    8.

     

    SHARED DISPOSITIVE POWER

    0 

         

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    1,913,5015

         

    10.

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

    o

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    3.6%8

         

    12.

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

    CO 

         

     

     

    7The record holder of the securities covered by this Schedule 13G is Ares Trading SA. Ares Trading SA is a dominantly controlled subsidiary of Merck Serono SA, Coinsins, Switzerland, an affiliate of Merck KGaA, Darmstadt, Germany. Merck Serono SA, Coinsins, Switzerland is a wholly owned indirect subsidiary of Merck KGaA, Darmstadt, Germany and E. Merck KG, Darmstadt, Germany. Merck KGaA, Darmstadt, Germany is a publicly traded company (Frankfurt Stock Exchange, DAX 40) and the beneficiary of the two companies. Merck KGaA, Darmstadt Germany is dominantly controlled by E. Merck KG, Darmstadt Germany. Merck Serono SA, Coinsins, Switzerland, an affiliate of Merck KGaA, Darmstadt, Germany and Merck KGaA, Darmstadt, Germany and E. Merck KG, Darmstadt, Germany may be deemed to possess voting and dispositive power with respect to the securities held of record by Ares Trading SA.
    8This percentage is based on 52,497,462 shares of Class A Common Stock outstanding (assuming the underwriters do not exercise in full the option to purchase additional shares), as disclosed by the Issuer in its Prospectus Supplement.

     

     

     

     

    Cusip No. 92337R101 13G Page 6 of 9 Pages

     

     

    Item 1(a). Name of Issuer:
      Vera Therapeutics, Inc.
       
    Item 1(b). Address of Issuer’s Principal Executive Offices:
      8000 Marina Blvd, Suite 120
      Brisbane, California 94005
       
    Item 2(a). Name of Person Filing:
     

    This Schedule 13G is being filed by each of the following persons (each, a “Reporting Person” and together, the “Reporting Persons”):

     

    Ares Trading SA

    Merck Serono SA, Coinsins, Switzerland, an affiliate of Merck KGaA, Darmstadt, Germany

    Merck KGaA, Darmstadt, Germany

    E. Merck KG, Darmstadt, Germany

     

    The Reporting Persons have entered into a Joint Filing Agreement, a copy of which is filed with this Schedule 13G as Exhibit 99.1, pursuant to which the Reporting Persons have agreed to file this Schedule 13G jointly in accordance with the provisions of Rule 13d-1(k)(l) of the Securities Exchange Act of 1934, as amended.

       
    Item 2(b). Address of Principal Business Office or, if none, Residence:
     

    Ares Trading SA: Zone Industrielle de l’Outriettaz, 1170 Aubonne, Switzerland

    Merck Serono SA: Zone Industrielle, 1267 Coinsins, Switzerland, an affiliate of Merck KGaA, Darmstadt, Germany

    Merck KGaA: Frankfurter Strasse 250, 64293 Darmstadt, Germany

    E. Merck KG: Emanuel-Merck-Platz 1, 64293 Darmstadt, Germany

       
    Item 2(c). Citizenship:
      The Reporting Persons Ares Trading SA and Merck Serono SA Coinsins, Switzerland, an affiliate of Merck KGaA, Darmstadt, Germany are organized in Switzerland. The Reporting Persons Merck KGaA and E. Merck KG are organized in Darmstadt, Germany.  
       
    Item 2(d). Title of Class of Securities:
      Common Stock, US$ 0.001 par value per share
       
    Item 2(e). CUSIP Number:
      92337R101
       
    Item 3. If this statement is filed pursuant to §§ 240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a:
     

     

    Not applicable

      (a) o Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o);
      (b) o Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c);
      (c) o Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c);
      (d) o Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
      (e) o An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
      (f) o An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
      (g) o A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
      (h) o A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
      (i) o A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act (15 U.S.C. 80a-3);
      (j) o A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J);
      (k) o Group, in accordance with § 240.13d-1(b)(1)(ii)(K).

     

     

     

     

    Cusip No. 92337R101 13G Page 7 of 9 Pages

     

     

    Item 4. Ownership:
      Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

      (a) Amount beneficially owned: 1,913,5019
         
      (b) Percent of class: 3.6%10
         
      (c) Number of shares as to which the person has:
         
        (i) Sole power to vote or to direct the vote: 1,913,5017
        (ii) Shared power to vote or to direct the vote: 0
        (iii) Sole power to dispose or to direct the disposition of: 1,913,5017
        (iv) Shared power to dispose or to direct the disposition of: 0

     

    Item 5. Ownership of Five Percent or Less of a Class:
      If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following o.
       
    Item 6. Ownership of More Than Five Percent on Behalf of Another Person:
      Not applicable 
       
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company:
      Not applicable 
       
    Item 8. Identification and Classification of Members of the Group:
      Not applicable
       
    Item 9. Notice of Dissolution of Group:
      Not applicable
       
    Item 10. Certifications:
      By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     

     

    9The record holder of the securities covered by this Schedule 13G is Ares Trading SA. Ares Trading SA is a dominantly controlled subsidiary of Merck Serono SA, Coinsins, Switzerland, an affiliate of Merck KGaA, Darmstadt, Germany. Merck Serono SA, Coinsins, Switzerland is a wholly owned indirect subsidiary of Merck KGaA, Darmstadt, Germany and E. Merck KG, Darmstadt Germany. Merck KGaA, Darmstadt, Germany is a publicly traded company (Frankfurt Stock Exchange, DAX 40) and the beneficiary of the two companies. Merck KGaA, Darmstadt Germany is dominantly controlled by E. Merck KG, Darmstadt Germany. Merck Serono SA, Coinsins, Switzerland, an affiliate of Merck KGaA, Darmstadt, Germany and Merck KGaA, Darmstadt, Germany and E. Merck KG, Darmstadt, Germany may be deemed to possess voting and dispositive power with respect to the securities held of record by Ares Trading SA.
    10This percentage is based on 52,497,462 shares of Class A Common Stock outstanding (assuming the underwriters do not exercise in full the option to purchase additional shares), as disclosed by the Issuer in its Prospectus Supplement.

     

     

     

     

    Cusip No. 92337R101 13G  

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    ARES TRADING SA   ARES TRADING SA  
         
    Date: February 14, 2024   Date: February 14, 2024
             
    By: /s/ Cedric Hyde   By: /s/ Florence Jolidon
             
    Name: Cedric Hyde   Name: Florence Jolidon
             
    Title: CFO   Title: Finance Manager

     

    MERCK SERONO SA, COINSINS, SWITZERLAND, AN AFFILIATE OF MERCK KGAA, DARMSTADT, GERMANY   MERCK SERONO SA, COINSINS, SWITZERLAND, AN AFFILIATE OF MERCK KGAA, DARMSTADT, GERMANY  
         
    Date: February 14, 2024   Date: February 14, 2024
             
    By: /s/ Cedric Hyde   By: /s/ Florence Jolidon
             
    Name: Cedric Hyde   Name: Florence Jolidon
             
    Title: CFO   Title: Finance Manager

     

    MERCK KGAA, DARMSTADT, GERMANY   MERCK KGAA, DARMSTADT, GERMANY  
         
    Date: February 14, 2024   Date: February 14, 2024
             
    By: /s/ Jens Eckhardt   By: /s/ Johannes Eckhardt
             
    Name: Jens Eckhardt   Name: Johannes Eckhardt
             
    Title: Head of Legal HC BD, Alliance Mgt, GMS & Governance   Title: Head of Legal – M&A, Ventures & Finance

     

    E.MERCK KG, DARMSTADT, GERMANY   E.MERCK KG, DARMSTADT, GERMANY
             
    Date: February 14, 2024   Date: February 14, 2024
             
    By: /s/ Johannes Eckhardt   By: /s/ Kristin Eibisch
             
    Name: Johannes Eckhardt   Name: Kristin Eibisch
             
    Title: Attorney-in-Fact   Title: Attorney-in-Fact

     

     

     

     

     

    Cusip No. 92337R101 13G  

     

    EXHIBIT INDEX

     

    Exhibit 99.1Joint Filing Agreement, dated January 26, 2023, by and between Ares Trading SA, Merck Serono SA, Coinsins, Switzerland, and Merck KGaA, Darmstadt, Germany and E.Merck KG, Darmstadt, Germany.
    Exhibit 99.2Power of Attorney

     

     

     

    Get the next $VERA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $VERA

    DatePrice TargetRatingAnalyst
    10/16/2025$48.00Buy
    BofA Securities
    8/4/2025Outperform → Peer Perform
    Wolfe Research
    5/5/2025$75.00Buy
    H.C. Wainwright
    2/4/2025$49.00Outperform
    Wolfe Research
    1/28/2025$58.00Buy
    Goldman
    11/21/2024$70.00Overweight
    Wells Fargo
    10/16/2024Sector Outperform
    Scotiabank
    1/25/2024$26.00Outperform
    Oppenheimer
    More analyst ratings

    $VERA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    BRISBANE, Calif., Feb. 06, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA) today announced that, on February 2, 2026, the Compensation Committee of the Board of Directors (Compensation Committee) of Vera Therapeutics granted inducement awards consisting of non-qualified stock options to purchase 11,500 shares of Class A common stock and restricted stock units (RSUs) underlying 5,750 shares of Class A common stock to two (2) new employees under the Vera Therapeutics, Inc. 2024 Inducement Plan (Inducement Plan). The Compensation Committee approved the awards as an inducement material to the new employees' employment in accordance with Nasdaq Listing Rule 5635(c)(4). Each stoc

    2/6/26 4:05:00 PM ET
    $VERA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vera Therapeutics Announces Appointment of Matt Skelton to Chief Commercial Officer

    BRISBANE, Calif., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced the appointment of Matt Skelton to Chief Commercial Officer, effective immediately. Mr. Skelton joined Vera Therapeutics over a year ago as the Executive Vice President, Commercial. "We are pleased to welcome Matt to the executive team as we prepare for the potential commercial launch of atacicept for the treatment of IgA nephropathy," said Marshall Fordyce, M.D., Founder and CEO of Vera Therapeutics. "With his track record

    1/28/26 7:30:00 AM ET
    $VERA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    BRISBANE, Calif., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA) today announced that, on January 5, 2026, the Compensation Committee of the Board of Directors of Vera Therapeutics granted inducement awards consisting of non-qualified stock options to purchase 228,750 shares of Class A common stock and restricted stock units (RSUs) underlying 116,000 shares of Class A common stock to eighteen (18) new employees under the Vera Therapeutics, Inc. 2024 Inducement Plan (Inducement Plan). The Compensation Committee approved the awards as an inducement material to the new employees' employment in accordance with Nasdaq Listing Rule 5635(c)(4). Each stock option granted

    1/9/26 1:05:00 PM ET
    $VERA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VERA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CHIEF FINANCIAL OFFICER Grant Sean was granted 25,000 shares, increasing direct ownership by 27% to 119,130 units (SEC Form 4)

    4 - Vera Therapeutics, Inc. (0001831828) (Issuer)

    2/6/26 8:00:13 PM ET
    $VERA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SVP, FINANCE, CHIEF ACCT OFFCR Young Joseph R was granted 10,000 shares, increasing direct ownership by 17% to 67,839 units (SEC Form 4)

    4 - Vera Therapeutics, Inc. (0001831828) (Issuer)

    2/6/26 8:00:16 PM ET
    $VERA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Commercial Officer Skelton Laurence Matthew was granted 20,000 shares, increasing direct ownership by 44% to 65,800 units (SEC Form 4)

    4 - Vera Therapeutics, Inc. (0001831828) (Issuer)

    2/6/26 8:00:11 PM ET
    $VERA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VERA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    BofA Securities initiated coverage on Vera Therapeutics with a new price target

    BofA Securities initiated coverage of Vera Therapeutics with a rating of Buy and set a new price target of $48.00

    10/16/25 8:29:17 AM ET
    $VERA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vera Therapeutics downgraded by Wolfe Research

    Wolfe Research downgraded Vera Therapeutics from Outperform to Peer Perform

    8/4/25 8:19:45 AM ET
    $VERA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H.C. Wainwright resumed coverage on Vera Therapeutics with a new price target

    H.C. Wainwright resumed coverage of Vera Therapeutics with a rating of Buy and set a new price target of $75.00

    5/5/25 9:37:24 AM ET
    $VERA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VERA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Enright Patrick G bought $249,985 worth of shares (5,882 units at $42.50) (SEC Form 4)

    4 - Vera Therapeutics, Inc. (0001831828) (Issuer)

    12/15/25 8:07:34 PM ET
    $VERA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Enright Patrick G bought $5,277,311 worth of shares (250,000 units at $21.11) (SEC Form 4)

    4 - Vera Therapeutics, Inc. (0001831828) (Issuer)

    6/25/25 8:07:16 PM ET
    $VERA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Katabi Maha bought $4,999,990 worth of shares (161,290 units at $31.00) (SEC Form 4)

    4 - Vera Therapeutics, Inc. (0001831828) (Issuer)

    2/1/24 5:58:54 PM ET
    $VERA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VERA
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Vera Therapeutics Inc.

    SCHEDULE 13G/A - Vera Therapeutics, Inc. (0001831828) (Subject)

    2/5/26 1:40:12 PM ET
    $VERA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SCHEDULE 13G filed by Vera Therapeutics Inc.

    SCHEDULE 13G - Vera Therapeutics, Inc. (0001831828) (Subject)

    1/30/26 2:43:55 PM ET
    $VERA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 8-K filed by Vera Therapeutics Inc.

    8-K - Vera Therapeutics, Inc. (0001831828) (Filer)

    12/17/25 7:50:30 PM ET
    $VERA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VERA
    Financials

    Live finance-specific insights

    View All

    Vera Therapeutics Announces Atacicept Achieved 46% Proteinuria Reduction in ORIGIN Phase 3 Trial in Adults with IgA Nephropathy

    Atacicept ORIGIN Phase 3 trial met the primary endpoint of reduction in proteinuria (UPCR) at week 36; participants receiving atacicept achieved a 46% reduction from baseline and 42% reduction compared to placebo at week 36 (p<0.0001)Other prespecified endpoints achieved similar or better results compared to the ORIGIN Phase 2b clinical trial — per FDA guidance, Vera is not sharing eGFR results at this time while the ORIGIN 3 placebo-controlled trial continuesThe safety profile of atacicept was favorable, and comparable to placebo Vera plans to meet with FDA in the coming weeks to discuss these results and the regulatory pathway; Vera currently plans to submit a Biologics License Application

    6/2/25 6:30:00 AM ET
    $VERA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vera Therapeutics Acquires Global Rights to Novel, Next Generation Dual BAFF/APRIL Inhibitor

    BRISBANE, Calif., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced an exclusive license agreement with Stanford University for a novel, next generation fusion protein targeting BAFF and APRIL, known as VT-109, with wide therapeutic potential across the spectrum of B cell mediated diseases. "This novel approach is part of Vera's broad lifecycle management strategy to expand and extend our leadership position within B cell modulation, which we believe has the potential to transform how we tre

    1/13/25 7:00:00 AM ET
    $VERA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vera Therapeutics Announces Positive Week 36 Efficacy and Safety Results of Phase 2b ORIGIN Clinical Trial of Atacicept in IgAN in Late-Breaking Presentation at 60th European Renal Association (ERA) Congress

    New data at week 36 shows atacicept 150 mg resulted in a delta of 43% versus placebo in mean proteinuria reduction in per-protocol analysis and demonstrated statistically significant stabilization of eGFR versus placebo in this high-risk population Atacicept was well tolerated with safety profile similar to placebo Positive results support atacicept 150 mg as a potential disease-modifying treatment for patients with IgA nephropathy; Phase 3 (ORIGIN 3) clinical trial initiated in June 2023 Conference call and webcast to take place on June 20th, 2023, at 8:00 a.m. ET to further discuss results BRISBANE, Calif., June 17, 2023 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a la

    6/17/23 10:10:00 AM ET
    $VERA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VERA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Vera Therapeutics Inc.

    SC 13G/A - Vera Therapeutics, Inc. (0001831828) (Subject)

    11/14/24 4:10:28 PM ET
    $VERA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Vera Therapeutics Inc.

    SC 13G/A - Vera Therapeutics, Inc. (0001831828) (Subject)

    11/14/24 4:05:17 PM ET
    $VERA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Vera Therapeutics Inc.

    SC 13G - Vera Therapeutics, Inc. (0001831828) (Subject)

    11/14/24 1:22:39 PM ET
    $VERA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VERA
    Leadership Updates

    Live Leadership Updates

    View All

    Vera Therapeutics Announces Appointment of Matt Skelton to Chief Commercial Officer

    BRISBANE, Calif., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced the appointment of Matt Skelton to Chief Commercial Officer, effective immediately. Mr. Skelton joined Vera Therapeutics over a year ago as the Executive Vice President, Commercial. "We are pleased to welcome Matt to the executive team as we prepare for the potential commercial launch of atacicept for the treatment of IgA nephropathy," said Marshall Fordyce, M.D., Founder and CEO of Vera Therapeutics. "With his track record

    1/28/26 7:30:00 AM ET
    $VERA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vera Therapeutics Appoints Veteran Biotech Executive James R. Meyers to its Board of Directors

    BRISBANE, Calif., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced the appointment of James R. Meyers, an accomplished biopharmaceutical executive with over three decades of commercial leadership experience to Vera Therapeutics' Board of Directors. "We are thrilled to welcome Jim to our Board of Directors at this pivotal point in Vera Therapeutics' history as we prepare to launch a potential first-in-class dual BAFF/APRIL inhibitor to transform the treatment of IgA nephropathy and other aut

    11/26/25 4:05:00 PM ET
    $VERA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vera Therapeutics Appoints Jason S. Carter as Chief Legal Officer

    BRISBANE, Calif., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced the appointment of Jason S. Carter as Chief Legal Officer, effective immediately. "We are excited to have Jason join our growing team. With our pivotal ORIGIN 3 trial of atacicept in IgAN on track to announce topline results in the second quarter of 2025 and planned BLA submission to the FDA anticipated later in the year, pending data, we are actively building out our team with experienced professionals who will help us succ

    11/18/24 8:00:00 AM ET
    $VERA
    Biotechnology: Pharmaceutical Preparations
    Health Care